US5066274A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Tetrapyrrole therapeutic agents
Assignee: PORPHYRIN PRODUCTS Inc 195 SOUTH SECOND WEST LOGAN UTAH 84321 A CORP OF UTAH
•
Filing: 1989-05-12
•
Granted: 1991-11-19
•
Expires: 2009-05-12
Abstract
Abstract This invention relates to a therapeutic composition for detection and/or treatment of mammalian tumors which comprises at least one fluorescent porphyrin containing at least three carboxylic acid groups and pharmaceutically acceptable salts thereof.
Inventors
- 👤 Jerry C. Bommer
- 👤 Bruce F. Burnham
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-28 02:16
CPC Classifications
A; A61; A61K; A61K51/00; A61K51/02; A61K51/04; A61K51/0474; A61K51/0485; A61K31/00; A61K31/33; A61K31/395; A61K31/40; A61K2123/00
Claims Analysis
Total Claims: 37
Claim 1
Independent Claim
54 words
A pharmaceutical composition for the detection of mammalian tumors which comprises a tumor detecting effective amount of a light-sensitive tetrapyrrole compound of the formula: ##STR8## or pharmaceutically acceptable salt thereof wherein ##STR9## and a pharmaceutical carrier therefor, wherein said compound is capable of being activated by light of sufficient wavelength to emit fluorescence thereof.
Claim 2
Dependent Claim
54 words
A pharmaceutical composition for the detection of mammalian tumors which comprises a tumor detecting effective amount of a light-sensitive tetrapyrrole compound of the formula: ##STR8## or pharmaceutically acceptable salt thereof wherein ##STR9## and a pharmaceutical carrier therefor, wherein said compound is capable of being activated by light of sufficient wavelength to emit fluorescence thereof.
Claim 3
Dependent Claim
20 words
The pharmaceutical composition according to claim 1 wherein X=H, vinyl, ethyl, acetyl or formyl; Y=methyl or formyl M=methyl and; E=ethyl
Claim 4
Dependent Claim
16 words
The pharmaceutical composition according to claim 1 wherein the tetrapyrrole compound is chlorin e 6 .
Claim 5
Dependent Claim
16 words
The pharmaceutical composition according to claim 1 wherein the tetrapyrrole compound is mesochlorin e 6 .
Claim 6
Dependent Claim
14 words
The pharmaceutical composition according to claim 1 wherein the tetrapyrrole compound is bacteriochlorin a.
Claim 7
Dependent Claim
16 words
The pharmaceutical composition according to claim 1 wherein the tetrapyrrole compound is 2-desvinylchlorin e 6 .
Claim 8
Dependent Claim
16 words
The pharmaceutical composition according to claim 1 wherein the tetrapyrrole compound is mesochlorin e 6 .
Claim 9
Dependent Claim
16 words
The pharmaceutical composition according to claim 1 wherein the tetrapyrrole compound is 2-acetylchlorin e 6 .
Claim 10
Dependent Claim
17 words
The pharmaceutical composition according to claim 1 wherein the tetrapyrrole compound is 2 formylchlorin e 6 .
Claim 11
Dependent Claim
16 words
The pharmaceutical composition according to claim 1 wherein the tetrapyrrole compound is rhodin g 7 .
Claim 12
Dependent Claim
68 words
A pharmaceutical composition for the treatment of tumors which comprises an anti-tumor effective amount of a light-sensitive tetrapyrrole compound of the formula: ##STR10## or pharmaceutically acceptable salts thereof wherein ##STR11## and a pharmaceutical carrier therefor, wherein said compound is capable of being activated by light of sufficient wavelength to exert a cell-killing effect on said tumor, with the proviso that said compound is not chlorin e 6 .
Claim 13
Dependent Claim
68 words
A pharmaceutical composition for the treatment of tumors which comprises an anti-tumor effective amount of a light-sensitive tetrapyrrole compound of the formula: ##STR10## or pharmaceutically acceptable salts thereof wherein ##STR11## and a pharmaceutical carrier therefor, wherein said compound is capable of being activated by light of sufficient wavelength to exert a cell-killing effect on said tumor, with the proviso that said compound is not chlorin e 6 .
Claim 14
Dependent Claim
18 words
The composition of claim 11 wherein X=H, vinyl, ethyl, acetyl or formyl Y=methyl or formyl M=methyl; and E=ethyl
Claim 15
Dependent Claim
16 words
The pharmaceutical composition according to claim 11 wherein the tetrapyrrole compound is mesochlorin e 6 .
Claim 16
Dependent Claim
14 words
The pharmaceutical composition according to claim 11 wherein the tetrapyrrole compound is bacteriochlorin a.
Claim 17
Dependent Claim
16 words
The pharmaceutical composition according to claim 11 wherein the tetrapyrrole compound is 2-desvinylchlorin e 6 .
Claim 18
Dependent Claim
16 words
The pharmaceutical composition according to claim 11 wherein the tetrapyrrole compound is 2-acetylchlorin e 6 .
Claim 19
Dependent Claim
16 words
The pharmaceutical composition according to claim 11 wherein the tetrapyrrole compound is 2-formylchlorin e 6 .
Claim 20
Dependent Claim
16 words
The pharmaceutical composition according to claim 11 wherein the tetrapyrrole compound is rhodin g 7 .
Claim 21
Dependent Claim
66 words
A method for the detection tumors in a mammal which comprises administering to said mammal an effective amount of a tetrapyrrole compound according to claim 1; applying light of sufficient wavelength to the area of the mammal to be examined, said wavelength being in the range of about 360 nm to about 760 nm, and observing emitted fluorescence from the tetrapyrrole compound located at said tumor.
Claim 22
Dependent Claim
19 words
The method according to claim 19 wherein X=H, vinyl, ethyl, acetyl or formyl; Y=methyl or formyl; M=methyl; and E=ethyl
Claim 23
Dependent Claim
16 words
The method according to claim 19 wherein the tetrapyrrole compound used is chlorin e 6 .
Claim 24
Dependent Claim
15 words
The method according to claim 19 wherein the tetrapyrrole compound is mesochlorin e 6 .
Claim 25
Dependent Claim
14 words
The method according to claim 19 wherein the tetrapyrrole compound used is bacteriochlorin a.
Claim 26
Dependent Claim
13 words
The method according to claim 19 wherein the tetrapyrrole compound used is 2-desvinylchlorin.
Claim 27
Dependent Claim
16 words
The method according to claim 19 wherein the tetrapyrrole compound used is 2-acetylchlorin e 6 .
Claim 28
Dependent Claim
16 words
The method according to claim 19 wherein the tetrapyrrole compound used is 2-formylchlorin e 6 .
Claim 29
Dependent Claim
16 words
The method according to claim 19 wherein the tetrapyrrole compound used is rhodin g 7 .
Claim 30
Dependent Claim
60 words
A method of treating tumors in mammals which comprises administering to said mammal an effective amount of the tetrapyrrole compound according to claim 11; applying light of sufficient wavelength and intensity to activate said tetrapyrrole compound, said wavelength being in the range from about 600 to about 800 nm, whereby said activated compound exerts a cell-killing effect on said tumor.
Claim 31
Dependent Claim
19 words
The method according to claim 28 wherein X=H, vinyl, ethyl, acetyl or formyl; Y=methyl or formyl M=methyl and; E=ethyl
Claim 32
Dependent Claim
16 words
The method according to claim 28 wherein the tetrapyrrole compound used is mesochlorin e 6 .
Claim 33
Dependent Claim
14 words
The method according to claim 28 wherein the tetrapyrrole compound used is bacteriochlorin a.
Claim 34
Dependent Claim
16 words
The method according to claim 28 wherein the tetrapyrrole compound used is 2-desvinylchlorin e 6 .
Claim 35
Dependent Claim
16 words
The method according to claim 28 wherein the tetrapyrrole compound used is 2-acetylchlorin e 6 .
Claim 36
Dependent Claim
16 words
The method according to claim 28 wherein the tetrapyrrole compound used is 2-formylchlorin e 6 .
Claim 37
Dependent Claim
16 words
The method according to claim 28 wherein the tetrapyrrole compound used is rhodin g 7 .
References Cited (Backward Citations)
FR834574A
Cited
US4104466A
Cited
US4393071A
Cited
DE2809093A1
Cited
EP0071991A2
Cited
WO1983000811A1
Cited
JPS58201793A
Cited
US4649151A
Cited
WO1984001382A1
Cited
US4541438A
Cited
US4634557A
Cited
EP0168832A2
Cited
US4675338A
Cited
US4693885A
Cited
EP0186962A1
Cited
US4656186A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-11-18 | 1995-05-20 | 1995-11-19 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-11-18 | 1999-05-20 | 1999-11-19 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-11-18 | 2003-05-20 | 2003-11-19 | $7700.00 | Window Closed / Lapsed |